Discovery of Dual Aβ/Tau Inhibitors and Evaluation of Their Therapeutic Effect on a Drosophila Model of Alzheimer’s Disease

Alzheimer’s disease (AD), the most common type of dementia, currently represents an extremely challenging and unmet medical need worldwide. Amyloid-β (Aβ) and Tau proteins are prototypical AD hallmarks, as well as validated drug targets. Accumulating evidence now suggests that they synergistically contribute to disease pathogenesis. This could not only help explain negative results from anti-Aβ clinical trials but also indicate that therapies solely directed at one of them may have to be reconsidered. Based on this, herein, we describe the development of a focused library of 2,4-thiazolidinedione (TZD)-based bivalent derivatives as dual Aβ and Tau aggregation inhibitors. The aggregating activity of the 24 synthesized derivatives was tested in intact Escherichia coli cells overexpressing Aβ42 and Tau proteins. We then evaluated their neuronal toxicity and ability to cross the blood–brain barrier (BBB), together with the in vitro interaction with the two isolated proteins. Finally, the most promising (most active, nontoxic, and BBB-permeable) compounds 22 and 23 were tested in vivo, in a Drosophila melanogaster model of AD. The carbazole derivative 22 (20 μM) showed extremely encouraging results, being able to improve both the lifespan and the climbing abilities of Aβ42 expressing flies and generating a better outcome than doxycycline (50 μM). Moreover, 22 proved to be able to decrease Aβ42 aggregates in the brains of the flies. We conclude that bivalent small molecules based on 22 deserve further attention as hits for dual Aβ/Tau aggregation inhibition in AD.

[1]  B. de Strooper,et al.  The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics , 2022, Nature Reviews Drug Discovery.

[2]  S. Graham,et al.  Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer’s Disease , 2021, Aging and disease.

[3]  A. Stringaro,et al.  New Pyrimidine and Pyridine Derivatives as Multitarget Cholinesterase Inhibitors: Design, Synthesis, and In Vitro and In Cellulo Evaluation , 2021, ACS chemical neuroscience.

[4]  Huanxiang Liu,et al.  Molecular dynamics simulations reveal the disruption mechanism of a 2,4‐thiazolidinedione derivative C30 against tau hexapeptide (PHF6) oligomer , 2021, Proteins.

[5]  M. Bajda,et al.  Dual Inhibitors of Amyloid-β and Tau Aggregation with Amyloid-β Disaggregating Properties: Extended In Cellulo, In Silico, and Kinetic Studies of Multifunctional Anti-Alzheimer’s Agents , 2021, ACS chemical neuroscience.

[6]  M. Zweckstetter,et al.  Doxycycline Interferes With Tau Aggregation and Reduces Its Neuronal Toxicity , 2021, Frontiers in Aging Neuroscience.

[7]  M. Bartolini,et al.  From Combinations to Single-Molecule Polypharmacology—Cromolyn-Ibuprofen Conjugates for Alzheimer’s Disease , 2021, Molecules.

[8]  Artur M. S. Silva,et al.  Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review. , 2021, European journal of medicinal chemistry.

[9]  B. Hyman,et al.  Synergy between amyloid-β and tau in Alzheimer’s disease , 2020, Nature Neuroscience.

[10]  J. Cummings,et al.  Alzheimer's disease drug development pipeline: 2020 , 2020, Alzheimer's & dementia.

[11]  Rosemary J. Jackson,et al.  Amyloid Beta and Tau Cooperate to Cause Reversible Behavioral and Transcriptional Deficits in a Model of Alzheimer’s Disease , 2019, Cell reports.

[12]  B. Malawska,et al.  1-Benzylpyrrolidine-3-amine-based BuChE inhibitors with anti-aggregating, antioxidant and metal-chelating properties as multifunctional agents against Alzheimer's disease. , 2019, European journal of medicinal chemistry.

[13]  R. Sabaté,et al.  Bacterial Inclusion Bodies for Anti-Amyloid Drug Discovery: Current and Future Screening Methods. , 2019, Current protein & peptide science.

[14]  I. Nelken,et al.  Tau impairs neural circuits, dominating amyloid-β effects, in Alzheimer models in vivo , 2018, Nature Neuroscience.

[15]  M. Bartolini,et al.  Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors. , 2018, Journal of medicinal chemistry.

[16]  K. Nilsson,et al.  Aggregated Aβ1-42 Is Selectively Toxic for Neurons, Whereas Glial Cells Produce Mature Fibrils with Low Toxicity in Drosophila. , 2018, Cell chemical biology.

[17]  R. Pi,et al.  Discovery of a novel multifunctional carbazole–aminoquinoline dimer for Alzheimer's disease: copper selective chelation, anti-amyloid aggregation, and neuroprotection , 2018, Medicinal Chemistry Research.

[18]  Dawid Panek,et al.  Advances toward multifunctional cholinesterase and β-amyloid aggregation inhibitors. , 2017, Future medicinal chemistry.

[19]  S. Prusiner,et al.  A 31-residue peptide induces aggregation of tau's microtubule-binding region in cells. , 2017, Nature chemistry.

[20]  C. Dong,et al.  Development of Phenothiazine-Based Theranostic Compounds That Act Both as Inhibitors of β-Amyloid Aggregation and as Imaging Probes for Amyloid Plaques in Alzheimer's Disease. , 2017, ACS chemical neuroscience.

[21]  E. Gazit,et al.  Cl-NQTrp Alleviates Tauopathy Symptoms in a Model Organism through the Inhibition of Tau Aggregation-Engendered Toxicity , 2016, Neurodegenerative Diseases.

[22]  R. Sabaté,et al.  Ultra rapid in vivo screening for anti-Alzheimer anti-amyloid drugs , 2016, Scientific Reports.

[23]  F. J. Luque,et al.  Novel Levetiracetam Derivatives That Are Effective against the Alzheimer-like Phenotype in Mice: Synthesis, in Vitro, ex Vivo, and in Vivo Efficacy Studies. , 2015, Journal of medicinal chemistry.

[24]  J. Kuret,et al.  Structure and mechanism of action of tau aggregation inhibitors. , 2014, Current Alzheimer research.

[25]  F. J. Luque,et al.  Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with β-amyloid and tau anti-aggregating properties. , 2014, Bioorganic & medicinal chemistry.

[26]  F. J. Luque,et al.  Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies. , 2014, European journal of medicinal chemistry.

[27]  F. J. Luque,et al.  Synthesis and multitarget biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents. , 2014, Journal of medicinal chemistry.

[28]  R. Sabaté,et al.  Thioflavin-S staining of bacterial inclusion bodies for the fast, simple, and inexpensive screening of amyloid aggregation inhibitors. , 2014, Current medicinal chemistry.

[29]  M. Bolognesi,et al.  Modulation of prion by small molecules: from monovalent to bivalent and multivalent ligands. , 2013, Current topics in medicinal chemistry.

[30]  R. Sabaté,et al.  Dual inhibitors of β-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates. , 2013, Current topics in medicinal chemistry.

[31]  Michael H. Hecht,et al.  A Novel Inhibitor of Amyloid β (Aβ) Peptide Aggregation , 2012, The Journal of Biological Chemistry.

[32]  T. Kálai,et al.  The Influence of Spin-Labeled Fluorene Compounds on the Assembly and Toxicity of the Aβ Peptide , 2012, PloS one.

[33]  K. Nilsson,et al.  Curcumin Promotes A-beta Fibrillation and Reduces Neurotoxicity in Transgenic Drosophila , 2012, PloS one.

[34]  F. J. Luque,et al.  Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases. , 2012, Journal of medicinal chemistry.

[35]  E. Speretta,et al.  Testing the Therapeutic Potential of Doxycycline in a Drosophila melanogaster Model of Alzheimer Disease* , 2011, The Journal of Biological Chemistry.

[36]  Fabio Biscarini,et al.  Kinetic characterization of amyloid-beta 1-42 aggregation with a multimethodological approach. , 2011, Analytical biochemistry.

[37]  Kai J. Kohlhoff,et al.  Detection of early locomotor abnormalities in a Drosophila model of Alzheimer's disease , 2011, Journal of Neuroscience Methods.

[38]  A. Mudher,et al.  Using Drosophila models of neurodegenerative diseases for drug discovery , 2011, Expert opinion on drug discovery.

[39]  C. Robinson,et al.  Trapping of palindromic ligands within native transthyretin prevents amyloid formation , 2010, Proceedings of the National Academy of Sciences.

[40]  J. Lehn,et al.  Cooperative, bottom‐up generation of rigid‐rod nanostructures through dynamic polymer chemistry , 2010 .

[41]  V. Andrisano,et al.  Bis(7)‐tacrine Derivatives as Multitarget‐Directed Ligands: Focus on Anticholinesterase and Antiamyloid Activities , 2010, ChemMedChem.

[42]  Amedeo Caflisch,et al.  Complete Phenotypic Recovery of an Alzheimer's Disease Model by a Quinone-Tryptophan Hybrid Aggregation Inhibitor , 2010, PloS one.

[43]  D. Sattelle,et al.  Alzheimer's disease: insights from Drosophila melanogaster models , 2010, Trends in biochemical sciences.

[44]  Zijing Li,et al.  Synthesis and evaluation of novel benzothiazole derivatives based on the bithiophene structure as potential radiotracers for beta-amyloid plaques in Alzheimer's disease. , 2010, Bioorganic & medicinal chemistry.

[45]  J. Johansson,et al.  Poly-N-methylated amyloid beta-peptide (Abeta) C-terminal fragments reduce Abeta toxicity in vitro and in Drosophila melanogaster. , 2009, Journal of medicinal chemistry.

[46]  Maria Laura Bolognesi,et al.  Docking Ligands on Protein Surfaces: The Case Study of Prion Protein. , 2009, Journal of chemical theory and computation.

[47]  C. Dobson,et al.  On the mechanism of nonspecific inhibitors of protein aggregation: dissecting the interactions of alpha-synuclein with Congo red and lacmoid. , 2009, Biochemistry.

[48]  P. Hof,et al.  Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses. , 2009, ACS chemical biology.

[49]  H. Vogel,et al.  Drosophila models of neurodegenerative diseases. , 2009, Annual review of pathology.

[50]  Jonathan Weissman,et al.  Small-molecule aggregates inhibit amyloid polymerization. , 2008, Nature chemical biology.

[51]  Maurizio Recanatini,et al.  Multi-target-directed ligands to combat neurodegenerative diseases. , 2008, Journal of medicinal chemistry.

[52]  J. Gestwicki,et al.  Structure–activity Relationships of Amyloid Beta‐aggregation Inhibitors Based on Curcumin: Influence of Linker Length and Flexibility , 2007, Chemical biology & drug design.

[53]  Richard M. Page,et al.  Intraneuronal Aβ, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer’s disease , 2005, Neuroscience.

[54]  Brian J Bacskai,et al.  In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers. , 2005, Angewandte Chemie.

[55]  Theodora M. Steindl,et al.  Structure-activity relationships and molecular modelling of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors. , 2005, Bioorganic & medicinal chemistry.

[56]  Li Di,et al.  High throughput artificial membrane permeability assay for blood-brain barrier. , 2003, European journal of medicinal chemistry.

[57]  V. Andrisano,et al.  beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. , 2003, Biochemical pharmacology.

[58]  Miratul M. K. Muqit,et al.  Modelling neurodegenerative diseases in Drosophila: a fruitful approach? , 2002, Nature Reviews Neuroscience.

[59]  W. Fann,et al.  Efficient light harvesting by sequential energy transfer across aggregates in polymers of finite conjugational segments with short aliphatic linkages. , 2001, Journal of the American Chemical Society.

[60]  E. Mandelkow,et al.  Tau in Alzheimer's disease. , 1998, Trends in cell biology.

[61]  H. Brodaty,et al.  ALZHEIMER'S DISEASE INTERNATIONAL , 1997, International journal of geriatric psychiatry.

[62]  N. Perrimon,et al.  Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. , 1993, Development.

[63]  C. W. Shoppee.  The Sommelet Reaction , 1948, Nature.

[64]  E. Gazit,et al.  Naphthoquinone-Tryptophan Hybrid Inhibits Aggregation of the Tau-Derived Peptide PHF6 and Reduces Neurotoxicity. , 2016, Journal of Alzheimer's disease : JAD.

[65]  A. Contestabile.  Cerebellar granule cells as a model to study mechanisms of neuronal apoptosis or survivalin vivo andin vitro , 2008, The Cerebellum.

[66]  L. Luo,et al.  A protocol for dissecting Drosophila melanogaster brains for live imaging or immunostaining , 2006, Nature Protocols.

[67]  D. Gubb,et al.  Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. , 2005, Neuroscience.